pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Genentech Inc

updated 2mo ago

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It operates as an independent subsidiary of holding company Roche. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval148 co-mentions · 74 sources
  • drugatezolizumab88 co-mentions · 44 sources
  • drugTECENTRIQ88 co-mentions · 44 sources
  • drugEVRYSDI32 co-mentions · 16 sources
  • drugrisdiplam32 co-mentions · 16 sources
  • tagSmall Molecule19 co-mentions · 19 sources
  • drugfaricimab10 co-mentions · 5 sources
  • drugVABYSMO10 co-mentions · 5 sources
pipeline
40
marketed
23
phase 3
2
catalysts ytd
9
approvals ytd
9
recalls ytd
0

Pipeline(40)

view full pipeline →
pipeline depth40 products
Phase 2: 4Phase 3: 2Marketed: 23Unknown: 10pre_registration: 1
4Phase 22Phase 323Marketed10Unknown1pre_registration
Marketed
(atezolizumab + hyaluronidase (human recombinant))
Hepatocellular Carcinoma
Marketed
(hyaluronidase (human recombinant) + ocrelizumab)
Primary Progressive Multiple Sclerosis (PPMS)
Marketed
(hyaluronidase (recombinant human) + pertuzumab + trastuzumab)
Human Epidermal Growth Factor Receptor 2 Positive Breast…
Marketed
(hyaluronidase (recombinant, human) + rituximab)
Chronic Lymphocytic Leukemia (CLL)
Marketed
(hyaluronidase (recombinant, human) + trastuzumab)
Breast Cancer
Marketed
EVRYSDI
Spinal Muscular Atrophy (SMA)
Marketed
alteplase
Acute Ischemic Stroke
Marketed
cobimetinib fumarate
Erdheim-Chester Disease (Erdheim–Chester Syndrome/ Polyos…
Marketed
dornase alfa
Cystic Fibrosis
Marketed
mosunetuzumab
Diffuse Large B-Cell Lymphoma
B-lymphocyte antigen CD20T cell surface glycoprotein CD3
Marketed
ocrelizumab
Primary Progressive Multiple Sclerosis (PPMS)
Marketed
omalizumab
Chronic Urticaria

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Genentech Inc jobs →

News

no news has mentioned this company yet
identifiers
source
globaldata
top tags
Oncology17DLBCL4Cardiology3Immunology3Breast Cancer2
mentioned in
0news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?